Related Experiment Video
Updated: Jun 3, 2026
11:34
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
Published on: April 29, 2017
[177Lu]DOTA-anti-CD20: labeling and pre-clinical studies
Paola F Audicio1, Gustavo Castellano, Marcos R Tassano
1Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo, Uruguay. paudicio@cin.edu.uy
Summary
Researchers developed a simple method to create a targeted cancer therapy using radiolabeled anti-CD20 antibody. This new therapeutic radiopharmaceutical, [(177)Lu]-DOTA-anti-CD20, shows high purity and stability for treating Non-Hodgkin
Area of Science:
- Nuclear medicine
- Oncology
- Immunotherapy
Background:
- Non-Hodgkin's Lymphoma (NHL) often expresses CD20 antigens.
- Rituximab (anti-CD20) is an effective targeted therapy for CD20-positive NHL.
- Radiopharmaceuticals offer targeted radiation delivery for cancer treatment.
Purpose of the Study:
- To develop a simple and efficient method for producing a novel therapeutic radiopharmaceutical, [(177)Lu]-DOTA-anti-CD20.
- To evaluate the radiochemical purity, stability, and biospecificity of the produced radiopharmaceutical.
- To assess the potential therapeutic efficacy using computational modeling.
Main Methods:
- Conjugation of anti-CD20 (Rituximab) to a bifunctional chelate (DOTA).
- Radiolabeling of the DOTA-conjugated antibody with Lutetium-177 ((177)Lu).
- Assessment of radiochemical purity, chemical and biological stability, and antigen binding.
- Monte Carlo simulation for dose deposition on a tumor model.
Main Results:
- [(177)Lu]-DOTA-anti-CD20 was successfully synthesized with high radiochemical purity (>97%).
- The radiopharmaceutical demonstrated good chemical and biological stability.
- Biospecificity for CD20 antigens was maintained.
- Simulations predicted significant radiation dose delivery to tumor models.
Conclusions:
- The developed method provides a viable approach for producing [(177)Lu]-DOTA-anti-CD20 as a therapeutic radiopharmaceutical.
- This agent shows promise for targeted radionuclide therapy in CD20-positive Non-Hodgkin's Lymphoma.
- Further studies are warranted to validate its clinical efficacy.
